Comparative pharmacokinetics of meloxicam in clinically normal horses and donkeys

American Journal of Veterinary Research

Volumn 67, Issue 6, 2006, Pages 1082-1085

  Sinclair, Melissa D ^a   Mealey, Katrina L ^b   Matthews, Nora S ^c   Peck, Ken E ^c   Taylor, Tex S ^c   Bennett, Brad S ^c  

^a UNIVERSITY OF GUELPH   (Canada)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; DISTRIBUTION VOLUME; DONKEY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORSE; MALE; MEAN RESIDENCE TIME; NONHUMAN; STEADY STATE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; EQUIDAE; FEMALE; HEALTH; HORSES; MALE; SPECIES SPECIFICITY; THIAZINES; THIAZOLES;

ANIMALIA; EQUIDAE; EQUUS ASINUS; EQUUS CABALLUS;

EID: 33745675447     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.6.1082     Document Type: Article

References (18)

1. MacAllister C. Nonsteroidal anti-inflammatory drugs: their mechanism of action and clinical use in horses. Vet Med 1994;89:237-240.
2. Livingston A. Mechanism of action of non-steroidal anti-inflammatory drugs. Vet Clin North Am: Small Animl Pract 2000;30:773-804.
3. Moses VS, Bertone AL. Nonsteroidal anti-inflammatory drugs. Vet Clin North Am Equine Pract 2002;18:21-37.
4. Lees P, Sedgwick AD, Higgins AJ, et al. Pharmacodynamics and pharmacokinetics of miloxicam in the horse. Br Vet J 1991;147:97-108.
5. Cross AR, Budsberg SC, Keefe TJ. Kinetic gait analysis assessment of meloxicam efficacy in a sodium urate-induced synovitis model in dogs. Am J Vet Res 1997;58:626-631.
6. Doig PA, Purbrick KA, Hare JE, et al. Clinical efficacy of meloxicam in dogs with chronic osteoarthritis. Can Vet J 2000;41:296-300.
7. Mathews KA, Pettifer G, Foster R, et al. Safety and efficacy of preoperative administration of meloxicam, compared with that of ketoprofen and butorphanol in dogs undergoing abdominal surgery. Am J Vet Res 2001;62:882-888.
8. Budsberg SC, Cross AR, Quandt JE, et al. Evaluation of intravenous administration of meloxicam for perioperative pain management following stifle joint surgery in dogs. Am J Vet Res 2002;63:1557-1563.
9. Jones CJ, Budsberg SC. Physiologic characteristics and clinical importance of the cyclooxygenase isoforms in dogs and cats. J Am Vet Med Assoc 2000;217:721-729.
10. Mealey KL, Matthews NS, Peck KE, et al. Comparative pharmacokinetics of phenylbutazone and its metabolite oxyphenbutizone in clinically normal horses and donkeys. Am J Vet Res 1997;58:53-55.
11. Coakley M, Peck KE, Taylor TS, et al. Pharmacokinetics of flunixin meglumine in donkeys, mules, and horses. Am J Vet Res 1999;60:1441-1444.
12. Peck KE, Ray AC, Manuel G, et al. Quantitation of phenylbutazone in equine sera by use of high performance liquid chromatography with a nonevaporative extraction technique. Am J Vet Res 1996;57:1522-1524.
13. Holford N, Benet L. Pharmacokinetics & pharmacodynamics: dose selection & the time course of drug action. In: Katzung B, ed. Basic & clinical pharmacology. 7th ed. Stamford, Conn: Appleton & Lange, 1998;34-49.
14. Busch U, Schmid J, Heinzel G, et al. Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab Dispos 1998;26:576-584.
15. Higgins AJ, Lees P. TaylorJB. Influence of phenylbutazone on eicosanoid levels in equine acute inflammatory exudates. Cornell Vet 1984;74:198-207.
16. Lees P, Higgins AJ. Flunixin inhibits prostaglandin production in equine inflammation. Res Vet Sci 1984;37:347-349.
17. Higgins AJ, Lees P. Arachidonic acid metabolites in carrageenin induced equine inflammatory exudates. J Vet Pharmacol Ther 1984;7:65-72.
18. Boothe D. Factors affecting drug disposition and extrapolation of dosing regimens. In: Boothe D, ed. Small animal clinical pharmacology and therapeutics. Philadelphia: WB Saunders Co, 2001;18-40.